Use of a Polyclonal Antibody for the Determination of the Prognostic Value of c-erbB-2 Protein Over-Expression in Human Breast Cancer

References

• Slamon D J, Clark G M, Wong S G, Levin W J, Ullrich A, McGuire W L. Human breast cancer: correlation of relapse and survival with amplification of the HER 2/neu oncogene. Science 1987; 235: 177–82
   PubMed Web of Science ®Google Scholar
• Borg A, Baldetorp B, Ferno M, Killander D, Olsson H, Sigurdsson H. ERBB2 amplification in breast cancer with high rate of proliferation. Oncogene 1991; 6: 137–43
   PubMed Web of Science ®Google Scholar
• May E, Mouriesse H, May-Levin F, Qian J F, May P, Delarue J C. Human breast cancer: identification of populations with a high risk of early relapse in relation to both oestrogen receptor status and c-erbB-2 overexpression. Br J Cancer 1990; 62: 430–5
   PubMed Web of Science ®Google Scholar
• Rilke F, Colnaghi M L, Cascinelli N, et al. Pronostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer 1991; 49: 44–9
   PubMed Web of Science ®Google Scholar
• Slamon D J, Godolphin W, Jones L A, et al. Studies of the HER 2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707–12
   PubMed Web of Science ®Google Scholar
• Tandon A K, Clark G M, Chamness G C, Ullrich A, McGuire W L. HER 2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989; 7: 1120–8
   PubMed Web of Science ®Google Scholar
• Tsuda H, Hirohashi S, Shimosato Y, et al. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-co-amplification units: hst.1/int.2 c-erbB-2/ear-1. Cancer Res 1989; 49: 3104–8
   PubMed Web of Science ®Google Scholar
• Wright C, Angus B, Nicholson S, et al. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res 1989; 49: 2087–90
   PubMed Web of Science ®Google Scholar
• Barnes D M, Lammie G A, Millis R R, Gullick W L, Allen D S, Altman D G. An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma. Br J Cancer 1988; 58: 488–52
   Web of Science ®Google Scholar
• Van de Vijver M J, Peterse J L, Maoi W J, et al. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in Stage II breast cancer. N Engl J Med 1988; 319: 1239–45
   PubMed Web of Science ®Google Scholar
• Zhou D J, Ahuji H, Cline M J. Proto-oncogene abnormalities in human breast cancer. c-erbB-2 amplification does not correlate with recurrence of disease. Oncogene 1989; 4: 105–8
   PubMed Web of Science ®Google Scholar
• National Institute of Health. Consensus development conference statement treatment of early stage breast cancer. National Institute of Health, Bethesda, MD 1990
   Google Scholar
• Naber S P, Tsutsumi Y, Yin S, et al. Strategies for the analysis of oncogene over expression. Am J Clin Pathol 1990; 94: 125–36
   PubMed Web of Science ®Google Scholar
• Slamon D J, Press M J, Godolphin W, et al. Studies of the HER 2/neu proto-oncogene in human breast cancer. Cancer Cells 1989; 7: 371–84
   Google Scholar
• Troalen F, Maudelonde T, Montcourrier P, Bohuon C, De-Larue J C. Characterization of two monoclonal antibodies against the COOH-terminal part of the human epidermal growth factor receptor and potential clinical use. J Immunol Methods 1991; 143: 175–86
   PubMed Web of Science ®Google Scholar
• May E, Mouriesse H, May-Levin F, Contesso G, Delarue J C. A new approach allowing an early prognosis in breast cancer: the ratio of estrogen receptor (ER) ligand binding activity to the ER-specific mRNA level. Oncogene 1989; 4: 1037–42
   PubMed Web of Science ®Google Scholar
• Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Measurem 1960; 20: 37–46
   Web of Science ®Google Scholar
• Allred D C, Clark G M, Tandon A K, et al. HER 2/neu in node negative breast cancer: prognostic significance of overpression influenced by the presence of in situ carcinoma. J Clin Oncol 1992; 10: 599–605
   PubMed Web of Science ®Google Scholar
• Borg A, Tandon A K, Sigurdsson H, et al. HER 2/neu amplification predicts poor survival in node positive breast cancer. Cancer Res 1990; 50: 4332–7
   PubMed Web of Science ®Google Scholar
• Gasparini G, Gullick W J, Bevilacqua P, et al. Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy and conventional pathologic features. J Clin Oncol 1992; 10: 686–95
   PubMed Web of Science ®Google Scholar
• Gusterson B A, Gelber R D, Goldhirsch A, et al. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 1992; 10: 1049–56
   PubMed Web of Science ®Google Scholar
• Lovekin C, Ellis I O, Locker A, et al. c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 1991; 63: 439–43
   PubMed Web of Science ®Google Scholar
• O'Reilly S M, Barnes D M, Camplejohn R S, Bartkova J, Gregory W M, Richards M A. The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer. Br J Cancer 1991; 63: 444–6
   PubMed Web of Science ®Google Scholar
• Thor A D, Schwartz L H, Koerner F C, et al. Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up. Cancer Res 1989; 49: 7147–52
   PubMed Web of Science ®Google Scholar
• Toikkanen S, Helin H, Joensuu H. Prognostic significance of HER 2 oncoprotein expression in breast cancer: A 30-year follow-up. J Clin Oncol 1992; 10: 1044–8
   PubMed Web of Science ®Google Scholar
• Tsuda H, Hirohashi S, Shimosato Y, et al. Immunohistochemical study on overexpression of c-erbB-2 protein in human breast cancer: its correlation with gene amplification and long-term survival of patients. Jpn J Cancer Res 1990; 81: 327–32
   PubMedGoogle Scholar
• Walker R A, Gullick W J, Varley J M. An evaluation of im-munoreactivity for c-erbB-2 protein as a marker of poor short-term prognosis in breast cancer. Br J Cancer 1989; 60: 426–9
   PubMed Web of Science ®Google Scholar
• Winstanley J, Cooke T, Murray G D, et al. The long term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer 1991; 63: 447–50
   PubMed Web of Science ®Google Scholar
• Gullick W J, Berger M S, Bennett P LP, et al. Expression of the c-erbB-2 protein in normal and transformed cells. Int J Cancer 1987; 40: 246–54
   PubMed Web of Science ®Google Scholar
• Berger M S, Locher G W, Saurer S, et al. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 1988; 48: 1238–43
   PubMed Web of Science ®Google Scholar
• Paik S, Hazan R, Fisher E R, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 1990; 8: 103–12
   PubMed Web of Science ®Google Scholar
• Kallioniemi O P, Holli K, Visakorpi T, Koivula T, Helin H H, Isola J J. Association of c-erbB-2 protein overexpression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 1991; 49: 650–5
   PubMed Web of Science ®Google Scholar
• McCann A H, Dervan P A, O'Regan M, et al. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. Cancer Res 1991; 51: 3296–303
   PubMed Web of Science ®Google Scholar
• De Potter C T, Beghin C, Makar A P, Vandekerckhove D, Roels H J. The neu-oncogene protein as a predictive factor for hæmatogenous metastases in breast cancer patients. Int J Cancer 1990; 45: 55–8
   PubMed Web of Science ®Google Scholar
• Baak J PA, Chin D, Van Diest P J, Ortiz R, Matze-Cok P, Bacus S S. Comparative long-term prognostic value of quantitative HER 2/neu protein expression, DNA ploidy and morphometric and clinical features in paraffin. Embedded invasive breast cancer. Lab Invest 1991; 64: 215–23
   PubMed Web of Science ®Google Scholar